Abstract
Recombinant bispecific antibodies have many different applications; especially promising is their therapeutic potential due to their ability to retarget an effector molecule or a cell to a disease-related target structure. In the last years, many formats have been developed: two commonly used are the bispecific diabody and the tandem scFv. In this chapter, the cloning, bacterial production, purification, and characterization of the two antibody formats are described in detail.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Withoff S et al (2001) Bispecific antibody therapy for the treatment of cancer. Curr Opin Mol Ther 3:353–362
Segal DM et al (1999) Bispecific antibodies in cancer therapy. Curr Opin Immunol 11:558–562
Cochlovius B et al (2000) Cure of Burkitt’s lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3  ×  CD19 tandem diabody, and CD28 costimulation. Cancer Res 60:4336–4341
Kontermann RE (2005) Recombinant bispecifc antibodies for cancer therapy. Acta Pharmacol Sin 26:1–9
Cao Y, Suresh MR (1998) Bispecific antibodies as novel bioconjugates. Bioconjug Chem 9(6):635–644
Löffler A et al (2000) A recombinant bispecific single-chain antibody, CD19  ×  CD2, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098–2103
Nettelbeck D et al (2001) Retargeting of adenoviruses to endothelial cells by a specific single-chain diabody directed against the adenovirus knob domain and human endoglin (CD105). Mol Ther 3:882–891
Haisma HJ et al (2000) Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther 7:901–904
Kriangkum J et al (2001) Bispecific and bifunctional single chain recombinant antibodies. Biomol Eng 18:31–40
Kontermann RE, Völkel T, Korn T (2004) Production of recombinant bispecific antibodies. In: Lo BKC (ed) Antibody engineering: methods and protocols, vol 248. Humana Press Inc., Totowa, New Jersey, pp 227–242
Chapman AP (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54:531–545
Stork R et al (2008) N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 283(12):7804–7812
Müller D et al (2007) Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 282(17):12650–12660
Stork R, Müller D, Kontermann RE (2007) A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel 20(11):569–576
Lu D et al (2004) The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant bispecific diabody. Biochem Biophys Res Commun 318:507–513
Holliger P (1993) “Diabodies”, small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 90:6444–6448
Perisic O et al (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure 2:1217–1226
Carmichael J et al (2003) The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in VL-to-VH orientation: implications for diabody flexibility. J Mol Biol 326:341–351
Korn T et al (2004) Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumor cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J Gene Med 6:642–651
Kranz DM, Gruber M, Wilson ER (1995) Properties of bispecific single chain antibodies expressed in Escherichia coli. J Hematother 4:403–408
Hayden MS et al (1994) Single-chain mono- and bispecific antibody derivates with novel biological properties and antitumor activity from a COS cell transient expression system. Ther Immunol 1:3–15
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Hornig, N., Färber-Schwarz, A. (2012). Production of Bispecific Antibodies: Diabodies and Tandem scFv. In: Chames, P. (eds) Antibody Engineering. Methods in Molecular Biology, vol 907. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-974-7_40
Download citation
DOI: https://doi.org/10.1007/978-1-61779-974-7_40
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-973-0
Online ISBN: 978-1-61779-974-7
eBook Packages: Springer Protocols